T lymphocyte engineering ex vivo for cancer and infectious disease

Expert Opinion on Biological Therapy

Volumn 8, Issue 4, 2008, Pages 475-489

  Levine, Bruce L ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive immunotherapy; Clinical trials; Gene therapy; T lymphocytes; Vaccines

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL SURVIVAL; CELL THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EX VIVO STUDY; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MELANOMA; MEMORY T LYMPHOCYTE; MYELOMA; NEUROBLASTOMA; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; COMMUNICABLE DISEASE; CULTURE TECHNIQUE; GENETICS; IMMUNOLOGY; LYMPHOCYTE TRANSFUSION; METHODOLOGY; NEOPLASM; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION; TREATMENT OUTCOME;

CANCER VACCINE; VACCINE;

ANIMALS; ANTIBODY FORMATION; CANCER VACCINES; CELL CULTURE TECHNIQUES; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; NEOPLASMS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; VACCINES;

EID: 42149096101     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.4.475     Document Type: Review

References (114)

1. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001;2(5):415-22
2. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Ann Rev Immunol 2004;22:745-63
3. Fearon DT, Manders P, Wagner SD. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 2001;293(5528):248-50
4. Opferman JT, Ober BT, Shton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 1999;283(5408):1745-8
5. Bouneaud C, Garcia Z, Kourilsky P, Pannetier C. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J Exp Med 2005;201(4):579-90
6. Chang JT, Palanivel VR, Kinjyo I, et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 2007;315(5819):1687-91
7. Maus MV, Kovacs B, Kwok WW, et al. Extensive replicative capacity of human central memory T cells. J Immunol 2004;172(11):6675-83
8. Weng NP, Palmer LD, Levine BL, et al. Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging. Immunol Rev 1997;160:43-54
9. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401(6754):708-12
10. + T cells confer superior antitumor immunity compared with effecror memory T cells. Proc Natl Acad Sci USA 2005;102(27):9571-6
11. + counterparts. J Immunol 1996;156(10):3587-90
12. - T cells in untreated hemato-oncological patients are expanded and display a Th1-type cytokine secretion profile, ex vivo cytolytic activity and enhanced tendency to apoptosis. Leukemia 1998;12(10):1573-82
13. Barber DL, Wherry EJ, Ahmed R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 2003;171(1):27-31
14. Sprent J, Surh CD. T cell memory. Ann Rev Immunol 2002;20:551-79
15. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4(8):595-602
16. Ossendorp F, Mengede E, Camps M, et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998;187(5):693-702
17. Schoenberger SP, Toes RE, van d V, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393(6684):480-3
18. + clones persist at higher levels in peripheral blood when IL-2 is also infused.
19. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99(11):3916-22
20. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005;11(11):1230-7 •• A randomized clinical trial showing the early reconstitution of lymphocytes and early induction of functional immunity to pneumococcus post stem cell transplantation following in vivo vaccine priming followed by the early infusion of primed and expanded T lymphocytes.
21. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004;114(9):1198-208
22. + cells or administration of anti-CD25 antibody can augment anti-tumor immunity.
23. + T reg cells. J Exp Med 2006;203(7):1701-11
24. Schuster SJ, Levine BL, Nasta S, et al. Adoptive immunotherapy with autologous CD25-depleted and CD3/CD28-costimulated T-cells (ACTC) enhances numeric and functional lymphocyte recovery after cyclophosphamide - fludarabine chemotherapy in patients with low-grade follicular lymphoma. Blood 2007;110(11):126
25. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766-72 • Evidence is presented that costimulation provided by triggering the CD28 receptor is able to increase CD25 expression and cytokine secretion in tumor-associated T cells.
26. Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12(7):758-69
27. + T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12(11):1150-60
28. Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107(4):1325-31
29. + cells. Semin Immunol 2006;18(2):78-88
30. Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 2002;8(6):1767-71
31. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-4 •• Evidence is presented that the addition of a non-myeloblative, but lymphodepleting conditioning regimen, showed, in contrast to previous studies, a robust engraftment of ex vivo-expanded tumor infiltrating lymphocytes. In 6 of 13 patients regression of metastatic melanoma was observed.
32. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997;15(2):796-807
33. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356(9232):802-7
34. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7(4):452-8
35. Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005;105(5):2132-4
36. Schmitz-Winnenthal FH, Volk C, Z'graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65(21):10079-87
37. Noonan K, Matsui W, Serafini P, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005;65(5):2026-34
38. Trickett A, Dwyer J, Tedla N, Lam-Po-Tang R. Safety and feasibility of harvesting cells for adoptive immunotherapy from patients with asymptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(5):523-4
39. Korbling M, Giralt S, Khouri I, et al. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher 2001;16(2):82-7
40. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
41. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201(2):241-8
42. Molldrem JJ. Vaccinating transplant recipients. Nat Med 2005;11(11):1162-3
43. Powell DJ Jr, Dudley ME, Hogan KA, et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 2006;177(9):6527-39
44. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006;134(1):64-76
45. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100(11):2757-65
46. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000;192(11):1637-44
47. + T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006;24(31):5060-9
48. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333(16):1038-44
49. + cytotoxic T cell clones could establish anti-viral immunity in vivo.
50. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345(8941):9-13 • Ex vivo-expanded and genetically marked EBV-specific donor derived CTL were shown to engraft and persist and were associated with clinical benefit in patients with EBV lymphoproliferative disease.
51. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2(5):551-5
52. Bollard CM, Savoldo B, Rooney CM, Heslop HE. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol 2003;110(2-3):139-48
53. Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999;96(18):10391-6
54. Gottschalk S, Heslop HE, Roon CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002;84:175-201
55. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12(10):1160-6 • This paper describes a novel strategy for the simultaneous expansion of T cells specific for CMV, EBV and adenovirus. EBV-transformed antigen presenting cell lines were genetically modified with chimeric adenoviral vectors encoding CMV antigen.
56. Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 2000;105(10):1407-17
57. Tan R, Xu X, Ogg GS, et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999;93(5):1506-10
58. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66
59. Figlin RA, Thompson JA, Bukowski RM, et al. Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999;17(8):2521-9
60. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002;51(10):539-46
61. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23(10):2346-57 • Extension of the results first reported in reference 31 to a total of 35 patients with refractory metastatic melanoma using selected and expanded TIL cultures.
62. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102(51):18538-43
63. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26(4):332-42 (1997)
64. Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003;101(7):2563-9 •• This follow up report on the first clinical trial of gene modified T cells shows the persistence of these cells for 12 years in a highly selective in vivo environment of congenital adenosine deaminase deficiency. Currently, genetically modified cells can be detected in each patient 16 years after infusion (L. Muul, pers. commun.).
65. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000;96(3):785-93
66. van Lunzen J, Glaunsinger T, Stahmer I, er al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007;15(5):1024-33
67. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288(5466):669-72
68. Available from: www.esgct.org/upload/X-SCID_statement_AT.pdf
69. Thrasher AJ, Gaspar HB, Baum C, et al. Gene therapy: X-SCID transgene leukaemogenicity. Nature 2006;443(7109):E5-6
70. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302(5644):415-9 • Following the development of leukemia in patients with severe combined immunodeficiency who had received retrovirally transduced hematopoietic stem cells, clonal proliferation of T cells was detected by TCR Vβ analysis. Tracking TCR Vβ clonality and integration site analysis is an important part of long-term follow up in gene transfer studies.
71. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103(46):17372-7 • The first clinical use of a lentiviral vector.
72. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24(6):687-96
73. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005;435(7042):646-51
74. Perez E, Jouvenot Y, Miller JC, et al. Towards gene knock out therapy for AIDS/HIV: targeted disruption of CCR5 using engineered Zinc Finger Protein Nucleases (ZFNs). Mol Ther 2007;13:S293
75. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001;248(1-2):67-76
76. Kershaw MH, Westwood JA, Parker LL, et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12(20 Pr 1):6106-15
77. Park JR, DiGiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15(4):825-33
78. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24(13):e20-2
79. Loskog A, Giandomenico V, Rossig C, et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006;20(10):1819-28 • Evidence is presented that the incorporation of the intracellular portion of the CD28 molecule fused to the CD3ζ-chain and CD19 single-chain Fv chimeric receptor shows that suppression induced by T regulatory cells can be overcome compared with chimeric receptor with CD3ζ alone in the intracellular portion.
80. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003;3(1):35-45
81. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005;105(1):13-21
82. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314(5796):126-9 • A clinical trial of redirected TCR gene-modified T cells shows engraftment and persistence of the modified cells, although only 2 of 17 patients demonstrated a sustained objective regression.
83. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007;109(1):235-43
84. Thomas S, Hart DP Xue SA, et al. T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin Biol Ther 2007;7(8):1207-18
85. Berger C, Berger M, Feng J, Riddell SR. Genetic modification of T cells for immunotherapy. Expert Opin Biol Ther 2007;7(8):1167-82
86. Evans LS, Witte PR, Feldhaus AL, et al. Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth. Hum Gene Ther 1999;10(12):1941-51 • Chimeric GM-CSFR/IL-2R receptors that deliver an IL-2 signal on binding GM-CSF, a novel design to address the issue of long-term survival of adoptively transferred CTLs, are described.
87. + memory effector T cells reconstitutes antigen-induced IL-2 production. J Exp Med 2003;198(6):947-55
88. Rufer N, Migliaccio M, Antonchuk J, et al. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001;98(3):597-603
89. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276(5319):1719-24
90. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007;109(11):4698-707 • A clinical demonstration that immune suppression of the patient and kinetics of graft versus tumor effect mediated by thymidine kinase-transduced donor lymphocytes in the setting of stem cell transplantation may allow the full exploitation of TK-DLI.
91. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2(2):216-23
92. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006;107(6):2294-302
93. Clackson T, Yang W, Rozamus LW, et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 1998;95(18):10437-42
94. Straathof KC, Spencer DM, Sutton RE, Rooney CM. Suicide genes as safety switches in T lymphocytes. Cytotherapy 2003;5(3):227-30
95. + T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 1995;7(6):891-904
96. + T cells in the absence of exogenous feeder cells. J Immunol 1997;159(12):5921-30
97. + T cell proliferation in HIV- positive patients as a result of CD28 costimulation. Science 1996;272(5270):1939-43
98. + T cells. Science 1997;276(5310):273-6
99. Renner C, Ohnesorge S, Held G, et al. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996;88(1):236-41
100. Bonyhadi M, Frohlich M, Rasmussen A, et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol 2005;174(4):2366-75
101. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20(2):143-8
102. Thomas AK, Maus MV, Shalaby WS, et al. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-rerm growth of CD4 T lymphocytes. Clin Immunol 2002;105(3):259-72
103. Suhoski MM, Golovina TN, Aqui NA, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther 2007;15(5):981-8 • Lentivirally transduced universal aAPCs for the activation and expansion of antigen-speficic and polyclonal T lymphocytes are described.
104. Smith B, Kasamon YL, Miller CB, et al. K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM). J Clin Oncol 2006;24(18S):6509
105. + T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile. J Immunol 2000;165(12):6908-14
106. Godfrey WR, Ge YG, Spoden DJ, et al. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004;104(2):453-61
107. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000;96(2):467-74
108. + T cells from HIV-1 infected donors following CD3/CD28 costimulation. J Hematotherapy 1998;7:437-48
109. Burger SR. Current regulatory issues in cell and tissue therapy. Cytotherapy 2003;5(4):289-98
110. Cross P, Levine BL. Assays for the release of cellular gene therapy products. In: Concepts in Genetic Medicine. Dropulic B, Carter B, editors. Hoboken, NJ, John Wiley & Sons; 2008
111. Rapoport AP, Levine BL, Badros A, et al. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant 2004;33(1):53-60
112. Andreadis C, Levine BL, Nasta SD, et al. Adaptive immunotherapy with autologous CD25-depleted and CD3/CD28-costimulated T-cells enhances lymphocyte recovery after cyclophosphamide - fludarabine chemotherapy in patients with low-grade follicular lymphoma. Blood 2006;108(11):2717
113. Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4(+) T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8(1):47-53
114. Kohn DB. Lentiviral vectors ready for prime-time. Nat Biotechnol 2007;25(1):65-6